Glenmark signs 10-yr marketing agreement with MeyerZall Labs

New Delhi, Oct 25 (UNI) Glenmark Pharmaceuticals Ltd (GPL) today said its South African arm has signed a 10-year marketing and distribution rights agreement with MeyerZall Laboratories that will help in expanding its topical dermatology portfolio.

''With the addition of these products to Glenmark's portfolio, we are now able to offer one of the widest topical dermatology baskets in the South African market adding significantly to our existing range and creating a niche in the area of dermatology for the company in South Africa,'' said company Director (Formulations) A S Mohanty.

In December 2005, GPL had acquired Bouwer Bartlett Pty Ltd, a South African sales and marketing company, through its wholly-owned Swiss subsidiary. Currently its pharmaceutical business unit produces, markets, sells and distributes a range of dermatological products.

''Therapeutic areas covered by this distribution agreement include psoriasis, fungal infections of the skin and inflammation with the following products now falling into the Glenmark portfolio: Linotar Gel 1, Covarex and Athru-Der,'' Mr Mohanty added.

Glenmark is one of the leading players in the Indian dermatology segment.

UNI